Prevalence of use and potential impact of increased use of primary care interventions to prevent cardiovascular hospitalizations in patients with diabetes

Diabetes Research and Clinical Practice

Volumn 85, Issue 3, 2009, Pages 328-334

  Luft, Vivian Cristine ^a   Giugliani, Camila ^a   Harzheim, Erno ^a   Schmidt, Maria Inês ^a   Duncan, Bruce Bartholow ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cardiovascular diseases; Diabetes complications; Diabetes mellitus; Hospitalization; Primary health care

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; INSULIN; METFORMIN; NICOTINE; PLACEBO; SULFONYLUREA;

ARTICLE; BEHAVIOR THEORY; BRAZIL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; DIET THERAPY; DISEASE CONTROL; HEALTH CARE UTILIZATION; HEALTH SURVEY; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLUENZA; MEDITERRANEAN DIET; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY MEDICAL CARE; RISK REDUCTION; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIET; EXERCISE; HOSPITALIZATION; HUMANS; HYPERTENSION; PREVALENCE; PRIMARY HEALTH CARE; RISK REDUCTION BEHAVIOR;

EID: 68249087189     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.06.026     Document Type: Article

References (29)

1. World Health Organization. Preventing chronic diseases: a vital investment: WHO global report [cited April 2, 2009]. Available from: http://www.who.int/chp/chronic_disease_report/contents/en/index.html.
2. Roglic G., Unwin N., Bennett P.H., Mathers C., Tuomilehto J., Nag S., et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diab. Care 28 (2005) 2130-2135
3. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diab. Care 27 (2004) 1047-1053
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865.
5. Gagliardino J.J. Resourcing issues. Eur. J. Endocrinol. 151 (2004) T9-11
6. Macinko J., Starfield B., and Shi L. The contribution of primary care systems to health outcomes within Organization for Economic Cooperation and Development (OECD) countries, 1970-1998. Health Serv. Res. 38 (2003) 831-865
7. Starfield B., Shi L., and Macinko J. Contribution of primary care to health systems and health. Milbank Q. 83 (2005) 457-502
8. Shi L., Macinko J., Starfield B., Politzer R., Wulu J., and Xu J. Primary care, social inequalities, and all-cause, heart disease, and cancer mortality in US counties 1990. Am. J. Public Health 95 (2005) 674-680
9. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Básica. Diabetes mellitus (Cadernos de Atenção Básica. Série A. Normas e Manuais Técnicos, 16). Brasília: Ministério da Saúde; 2006 [cited 2009 April 2]. Available from: http://dtr2004.saude.gov.br/dab/docs/publicacoes/cadernos_ab/abcad16.pdf.
10. Harzheim E., Duncan B.B., Stein A.T., Cunha C.R., Goncalves M.R., Trindade T.G., et al. Quality and effectiveness of different approaches to primary care delivery in Brazil. BMC Health Serv. Res. 6 (2006) 156
11. Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., Cutler J., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165 (2005) 1410-1419
12. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F., Neal B., Pfeffer M., Kostis J., Algert C., et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertens. 25 (2007) 951-958
13. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., et al. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
14. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., and Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med. 348 (2003) 1322-1332
15. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
16. de Lorgeril M., Salen P., Martin J.L., Monjaud I., Delaye J., and Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99 (1999) 779-785
17. Taylor R.S., Brown A., Ebrahim S., Jolliffe J., Noorani H., Rees K., et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am. J. Med. 116 (2004) 682-692
18. Mohiuddin S.M., Mooss A.N., Hunter C.B., Grollmes T.L., Cloutier D.A., and Hilleman D.E. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 131 (2007) 446-452
19. Attia J., Page J., Heller R.F., and Dobson A.J. Impact numbers in health policy decisions. J. Epidemiol. Community Health 56 (2002) 600-605
20. Heller R.F., Edwards R., and McElduff P. Implementing guidelines in primary care: can population impact measures help?. BMC Public Health 3 (2003) 7
21. Rosa R.S. Diabetes Mellitus: magnitude das hospitalizações na rede pública do Brasil, 1999-2001. Epidemiology [thesis]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2006.
22. Kuchenbecker R. Impacto clínico e econômico de um plano estruturado de alta hospitalar a pacientes portadores de Diabetes Mellitus tipo 2 e cardiopatia isquêmica. Epidemiology [thesis]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2006.
23. Clarke P.M., Gray A.M., Briggs A., Stevens R.J., Matthews D.R., Holman R.R., et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 48 (2005) 868-877
24. Heart Protection Study Collaborative, Mihaylova B., Briggs A., Armitage J., Parish S., Gray A., et al. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20536 people. BMJ 333 (2006) 1145
25. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 (2002) 2542-2551
26. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348 (2003) 383-393
27. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337 (2008) a1840
28. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008) 2134-2141
29. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 (2003) 1423